---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-017641"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2026-02-18T23:59:59+00:00"
generated_at: "2026-05-16T02:06:55.577807+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics enrolls 545 patients in SYMON™ II study, exceeds expectations

## Summary
- Enrolled 545 of 750 target patients in SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations.
- Completed monoclonal and polyclonal antibody production, providing capacity for >10 million test cartridges.
- Manufacturing readiness includes cartridge characterization for U.S. commercial production and ongoing fabrication for FDA submission.
- Company transitions focus to data analysis, regulatory engagement, and commercialization preparedness in 2026.
- Technology transfer activities progress without single point of failure, mitigating scale-up risk.

## SEC filing metadata
- accession: 0001213900-26-017641
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2026-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390026017641/0001213900-26-017641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390026017641/ea0277474-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-017641
- JSON: https://secwatch.observer/filing/0001213900-26-017641.json
- Plain text: https://secwatch.observer/filing/0001213900-26-017641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.